Literature DB >> 31691993

The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study.

Jiaofeng Huang1, Mengli Jing2, Ciyang Wang2, Mingfang Wang1, Shunjie You2, Su Lin1, Yueyong Zhu1.   

Abstract

BACKGROUND: We aimed to explore the impact of hepatitis B virus (HBV) infection on the prevalence of nonalcoholic fatty liver disease (NAFLD) based on clinical big data.
METHODS: Data were collected from the health examination center of the First Affiliated Hospital of Fujian Medical University. Univariate and multivariate analysis were applied to investigate the relationship between HBV and NAFLD.
RESULTS: A total of 14 452 patients were included, with an average age of 43.84 ± 13.03 years. Cases of HBV current infection, past infection, and noninfection were 21 102 110 (14.6%), 90 039 003 (62.3%), and 33 393 339 (23.1%), respectively. The prevalence of NAFLD was significantly lower in the current infection group (29.9%) than in the past infection group (35.8%) and noninfection group (31.9%) (P < .001). After adjusting for age, the prevalence of NAFLD in the current infection group remained the lowest across all of the age groups. Multivariate analysis showed that current infection was at a lower risk of NAFLD (odds ratio [OR] = 0.717, 95% CI: 0.608-0.846), whereas past infection had no effect on NAFLD.
CONCLUSIONS: Current HBV infection may lower the risk of NAFLD. This effect becomes insignificant when the patient is no longer infected.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  hepatitis B e antigen; hepatitis B surface antigen; hepatitis B virus; nonalcoholic fatty liver

Mesh:

Year:  2019        PMID: 31691993     DOI: 10.1002/jmv.25621

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.

Authors:  Ming-Fang Wang; Bo Wan; Yin-Lian Wu; Jiao-Feng Huang; Yue-Yong Zhu; You-Bing Li
Journal:  World J Gastroenterol       Date:  2021-01-28       Impact factor: 5.742

2.  MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease.

Authors:  Rahul Kumar; Su Lin; Jiaofeng Huang; Weijie Ou; Mingfang Wang; Medha Singh; Yuxiu Liu; Shiying Liu; Yinlian Wu; Yueyong Zhu
Journal:  Risk Manag Healthc Policy       Date:  2021-02-09

3.  The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection.

Authors:  Hiroyuki Amano; Tatsuo Kanda; Hitoshi Mochizuki; Yuichiro Kojima; Yoji Suzuki; Kenji Hosoda; Hiroshi Ashizawa; Yuko Miura; Shotaro Tsunoda; Yosuke Hirotsu; Hiroshi Ohyama; Naoya Kato; Mitsuhiko Moriyama; Shuntaro Obi; Masao Omata
Journal:  Viruses       Date:  2021-11-04       Impact factor: 5.048

Review 4.  Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.

Authors:  Yi-Wen Shi; Rui-Xu Yang; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

5.  Prevalence and Incidence of Non-alcohol Fatty Liver Disease in Chronic Hepatitis B Population in Southeast China: A Community-Based Study.

Authors:  Yang Zheng; Kaijin Xu; Haiyang Hu; Mohamed S Draz; Wei Wu; Lanjuan Li
Journal:  Front Med (Lausanne)       Date:  2021-07-19

6.  MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.

Authors:  Jiaofeng Huang; Wenjuan Xue; Mingfang Wang; Yinlian Wu; Medha Singh; Yueyong Zhu; Rahul Kumar; Su Lin
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-27       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.